ERBB2 and colorectal carcinoma: By immunohistochemistry, Yao et al. found that receptor tyrosine kinase (RTK) members ErbB2, ErbB3, and c-Met were indeed differentially overexpressed in samples from CRC patients, leading to constitutive activation of RTK signaling pathways.